2026-04-17T11:36:08Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1732582025-12-05T11:56:00Zcom_2072_1057col_2072_478916col_2072_478917
RECERCAT
author
Gensthaler, Lisa
author
Joura, Elmar A.
author
Alemany i Vilches, Laia
author
Horvat, Reinhard
author
Sanjosé Llongueras, Silvia de
author
Pils, Sophie
2021-01-20T17:30:13Z2021-01-20T17:30:13Z2020-03-012020-12-21T13:16:45Z
Purpose To evaluate HPV and p16(ink4a) status as prognostic factors in patients with invasive vulvar cancer. Methods Retrospective analysis of disease-free (DFS) and disease-specific survival (DSS) of patients with invasive vulvar cancer at a single tertiary care center. Histology, HPV and p16(ink4a) status were evaluated in the context of a global multicenter trial. Logistic regression models were performed to identify the impact of p16(ink4a) positivity. Results 135 patients were included in the analysis. 32 (23.7%) showed a p16(ink4a) expression of over 25%. Disease-free and disease-specific survival was longer in p16(ink4a) positive patients (23 vs. 10 months, p = 0.004, respectively, 29 vs. 21 months, p = 0.016). In multivariate analysis, p16(ink4a) positivity was an independent parameter for DFS (p = 0.025, HR: 2.120 (1.100-4.085)), but not for DSS (p = 0.926, HR: 1.029 (0.558-1.901), in contrast to age and tumor stage. Conclusions Age and tumor stage negatively affect survival. However, disease-free survival is significantly longer in patients with p16(ink4a) positive invasive vulvar cancer.
cc by (c) Gensthaler et al., 2020 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess
Papil·lomavirus
Càncer ginecològic
Pronòstic mèdic
Papillomaviruses
Gynecologic cancer
Prognosis
The impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion